Pure Global
NCT06409832

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)
University of Florence·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine
Drug/Device/Intervention
Rimegepant 75 mg
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
University of Florence
Location
Florence,Pavia, Italy
Timeline & enrollment
Phase
N/A
Start date
Mar 26, 2024
End date
Jan 01, 2026
Enrollment
100 participants
Primary outcome

Changes in migraine frequency after three months of treatment,Percentage of 50% Responders (namely patients who presented a reduction of MMDs / = 50% compared to baseline) after three months of treatment with rimegepant

Summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and
 tolerability of rimegepant as preventive migraine treatment in a cohort of episodic or
 chronic migraine patients.

ICD-10 classifications
Migraine without aura [common migraine]Migraine with aura [classical migraine]Other migraineMigraineMigraine, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409832
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06409832 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Florence and is currently Recruiting. The study focuses on Migraine,Migraine With Aura,Migraine Without Aura,Chronic Migraine. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.